Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk?

Non-alcoholic fatty liver disease (NAFLD), newly renamed metabolic dysfunction-associated steatotic liver disease (MASLD),[1] has a worldwide prevalence of at least 30% among adults and is becoming the leading cause of liver cirrhosis and hepatocellular carcinoma (HCC).[2] Since only a minority of subjects with MASLD progress towards liver-related events (LRE), risk stratification is crucial to optimize the allocation of resources for the care of MASLD individuals. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis. [Extracted from the article]